INTRODUCTION
============

Oral aspirin challenge is the best method of diagnosing nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NERD), but this is a time-consuming procedure that results in serious complications in some cases. Therefore, the development of noninvasive biomarkers for easy diagnosis has been attempted to confirm the diagnosis of NERD and prevent unexpected complications of nonsteroidal anti-inflammatory drugs (NSAIDs)/aspirin use in susceptible patients. Using several genetic approaches, including biologically plausible candidate genes and genome-wide association studies (GWAS), more than 100 genetic variants have been identified in association with NERD. Among them, the best mechanistic evidence supports intrinsic dysregulation of the leukotriene (LT)/prostaglandin (PG) pathway, leading to increased recruitment of eosinophils and immune effector cells into the target tissues. These effects are mainly mediated by single nucleotide polymorphisms (SNPs) of the genes that regulate mRNA and protein expression responsible for PG and LT metabolism, i.e., *LTC4S*,[@B1][@B2] *ALOX5*,[@B3][@B4] *CYSLTR1*,[@B5][@B6][@B7] *CYSLTR2*,[@B5][@B6] *TBX*,[@B6][@B8] *EP2*,[@B9] and *COX2*[@B10][@B11] ([Table 1](#T1){ref-type="table"}).

###### NERD-associated single nucleotide polymorphisms in the genes for cysteinyl LTRs, PG, and thromboxane synthesis and their receptors

![](aair-11-779-i001)

  Gene          Locus           rsnumber                                Genotype                                     Race                               No. of study subjects (AIA/ATA)    MAF (AIA/ATA)       *P* value                OR (95% CI)         AF                  Reference (PMID)
  ------------- --------------- --------------------------------------- -------------------------------------------- ---------------------------------- ---------------------------------- ------------------- ------------------------ ------------------- ------------------- ------------------
  LTC4S         Promoter        rs730012                                −444 A\>C                                    Polish                             76/110                             0.39/0.27           0.01                     2.61 (1.38--4.98)   0.50 (0.35--0.66)   10970818
  Japanese      60/100          0.19/0.11                               0.042                                        1.88 (0.91--3.87)                  0.26 (0.14--0.42)                  12063521                                                                             
  American      51/33           0.27/0.33                               Negative                                     \-                                                                    10887308                                                                             
  Korean        93/181          0.14/0.18                               Negative                                     \-                                                                    14749922                                                                             
  ALOX5         Promoter        \-                                      VNTR                                         American                           6/25                               \-                  \< 0.05 (Luc activity)   \-                                      9062372
  Japanese      55/63           Negative                                12063521                                                                                                                                                                                                
  HT1           \-              (G-C-G-A)                               Korean                                       93/181                             0.69/0.36                          0.01                5.0 (1.54--17.9)         0.77 (0.51--0.92)   14749922            
  CysLTR1       Promoter        rs321029                                −634 C\>T                                    Korean                             105/110                            \-                  0.02 in male             2.89 (1.14--7.28)                       16630147
  Novel         −475 A\>C                                                                                                                                                                                                                                                       
  Novel         −336 A\>G                                                                                                                                                                                                                                                       
  Exon1         Novel           927 T\>C                                UK                                           341 asthmatic families             \-                                 \-                  \-                                           16776674            
  \-            Spanish         87 (41 asthma with atopic dermatitis)   0.47/0.08                                    \< 0.008 in male                   9.78 (1.73--55.30)                 0.82 (0.44--0.96)   16846449                                                         
  Exon3         Novel           899 G\>A                                Tristan da Cunha                             52/60 (atopic/non-atopic asthma)   0.11/0.03                          \< 0.0001           6.28 (2.2--17.7)         0.40 (0.19--0.66)   17558309            
  CysLTR2       Exon            rs41347648                              601 G\>A                                     Caucasian                          1st 359, 2nd 384 asthma families   0.03                0.04                     \-                                      15475736
  Promoter      Novel           −1220 A\>C                              Japanese                                     137 asthmatic families             0.93                               0.0066              \-                                           15454733            
  Promoter      rs7324991       −819 T\>G                               Korean                                       66/134                             0.51/0.43                          0.031               2.04 (1.06--3.85)        0.51 (0.35--0.66)                       
  3\'UTR        Novel           +2078 C\>T                                                                                                              0.44/0.30                          0.013               2.28 (1.19--4.40)        0.50 (0.34--0.66)   15970796            
  rs912278      +2534 A\>G      0.47/0.39                               0.031                                        2.02 (1.07--3.84)                  0.48 (0.33--0.64)                                                                                                       
  PTGER1        3\'UTR          rs2241363                               −500 G\>C                                    Korean                             268/137                            0.42/0.36                                    0.37 (0.19--0.73)   0.13 (0.07--0.23)   
  PTGER2        5\'-up-stream   Novel                                   −12813 G\>A                                  Japanese                           198/282/274                        0.31/0.22/0.22      0.0017                   3.21 (1.53--6.75)   0.50 (0.32--0.67)   15898979
  −10814 T\>A   0.49/0.39       0.0025                                                                                                                                                                                                                                          
  Promoter      \-              −6179 A\>G                              Korean                                       108/93                             0.37/0.45                          0.0199              \-                                                               
  rs2075797     −616 C\>G       0.34/0.44                               0.039                                        0.64 (0.42--0.98)                  0.17 (0.12--0.25)                  17496729                                                                             
  rs1353411     −166 G\>A       0.45/0.38                               0.023                                        2.60 (1.14--5.92)                  0.53 (0.33--0.72)                                                                                                       
  PTGER3        Promoter        rs7551789                               −1709 T\>A                                   Korean                             108/93                             0.38/0.30           0.043                    3.02 (1.04--8.80)   0.53 (0.28--0.77)   
  Intron        rs7543182       A\>C                                    243/919                                      0.29/0.24                          0.02                               1.31 (1.04--1.66)   0.27 (0.23--0.32)        15632198                                
  3\'UTR        rs959           A\>G                                                                                 0.44/0.38                          0.005                              1.36 (1.10--1.68)   0.37 (0.33--0.42)        17496729                                
  PTGER4        Promoter        Novel                                   −1254 A\>G                                   Korean                             108/93                             0.28/0.20           0.018                    1.90 (1.12--3.22)   0.34 (0.23--0.47)   17496729
  PTGIR         3\'UTR          rs1126510                               +1915 T\>C                                   Korean                             108/93                             0.06/0.13           0.015                    0.37 (0.17--0.83)   0.02(0.01--0.04)    21449675
  PTGDR         Diplotype       \-                                      CCCT/CCCC (−613CC, −549CC, −441CC, −197TC)   Spanish                            75/51                              0.11/0.10           \-                       \-                                      23101307
  TBXAS1        Intron 9        rs692291                                +141931 T\>A                                 Korean                             115/270                            0.38/0.49           0.04                     0.27 (0.13--0.57)   0.09 (0.04--0.18)   
  TBXA2R        Exon3           rs11085026                              +795 T\>C                                    Korean                             93/172                             0.41/0.36           0.009                    \-                                      15898979
  Promoter      rs4807491       −4684 C\>T                                                                           108/93                             0.46/0.43                          0.032               2.57 (1.09--6.09)        0.54 (0.33--0.73)   17496729            
  0.39/0.47     0.027           0.42 (0.19--0.91)                       0.14 (0.06--0.26)                                                                                                                                                                                       

NERD, nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease; LTR, leukotriene; PG, prostaglandin; AF, attributable fraction; AIA, aspirin-induced asthma; ATA, aspirin-tolerance asthma; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; LTC4S, leukotriene C4 synthase; ALOX5, arachidonate 5-lipoxygenase; CysLTR1, cysteinyl leukotriene receptor 1; CysLTR2, cysteinyl leukotriene receptor 2; PTGER2, prostaglandin E receptor 2; PTGER3, prostaglandin E receptor 3; PTGER4, prostaglandin E receptor 4; PTGIR, prostaglandin I2 receptor; TBXAS1, thromboxane A synthase 1; TBXA2R, thromboxane A2 receptor; RGS7BP, regulator of G protein signaling 7-binding protein.

An LTC4S−444A/C promoter SNP (rs730012) is among the most widely reported variants associated with NERD, although its association with NERD across studies is inconsistent.[@B12][@B13][@B14][@B15][@B16] Three ALOX5 promoter variants have been shown to be associated with NERD and/or its severity of hyperresponsiveness.[@B4][@B17][@B18] However, some results have not been replicated due to small sample sizes, ethnic differences between study populations, or epigenetic changes, for the latter of which there is compelling evidence for a role in NERD.[@B19][@B20]

CLINICAL EVIDENCE OF EPIGENETIC COMPONENTS IN NERD
==================================================

The prevalence of NSAID/aspirin hypersensitivity in adult asthmatics varies depending on the method used for diagnosis. In a recent meta-analysis,[@B21] the prevalence was highest when determined by oral provocation test (adults 21%, children 5%), as compared to verbal history (adults 3%, children 2%). In Korea, 6.2% of 836 adult asthmatics showed a positive responses to oral aspirin challenge tests,[@B22] and 5.8% of 1,173 adult asthmatics showed a positive response for NSAID/aspirin hypersensitivity n histories and/or provocation tests.[@B23] NERD shows less familial aggregation compared with asthma, although the European Network on Aspirin-Induced Asthma found that 6% of NERD patients had a family history of aspirin hypersensitivity.[@B24];a study of 1,344 Turkish patients revealed a 3.7% family history of NSAID/aspirin hypersensitivity,[@B25] suggesting an intermediate genetic background for this condition.

NSAID/aspirin hypersensitivity is more common in women than in men, beginning in adulthood at an average age of 30 years. Once developed, it remains throughout life, although sporadic disappearance of intolerance has been reported.[@B26] However, considerable discordance in clinical manifestations of the disease has been noted in identical twin sisters, suggesting the greater influence of environmental factors.[@B27][@B28] As NERD usually develops in middle age after relatively long-term exposure to NSAIDs, and with a low level of familial aggregation,[@B24][@B29] epigenetic mechanisms may make greater contributions than genetic variations.

GLOBAL CHANGES IN CpG METHYLATION OF NASAL POLYPS FROM SUBJECTS WITH NERD
=========================================================================

Epidemiological studies have shown that regular use of NSAIDs reduces the risk of development of at least some cancers.[@B30][@B31] via the well-known targets, including *COX-1* and *COX-2*, and other intracellular pathways, including cell cycle, cell differentiation, apoptosis, and regulation of transcription factors (TFs).[@B32] In our previous *in vitro* study, *DNMT3a* and 3b mRNAs were elevated in a mucoepidermoid cell line (NCI-H292) within 1 day after stimulation with medium and high doses of aspirin, while *DNMT1* and *MeCP2* showed no significant changes in expression ([Fig. 1](#F1){ref-type="fig"}). *DNMT3b* mRNA was enhanced by stimulation for 2 hours with 0.2 and 2 mM aspirin. *DNMT3a* mRNA level was increased progressively for up to 3 days by treatment with high-dose aspirin. These data suggest that aspirin may induce global CpG methylation, which may affect gene expression. In contrast, NSAIDs are known induce promoter demethylation of Secreted Protein Acidic and Cysteine Rich (*SPARC*) by repressing DNMT expression.[@B33] In agreement with the experimental data, an epidemiological study showed that chronic aspirin use may be associated with a lower prevalence of E-cadherin (*CDH1*) promoter methylation in non-neoplastic gastric mucosa.[@B34]

![Effects of aspirin on DNA methyltransferase genes in the mucoepidermoid NCI-H292 lung cell line. Quantitative real-time polymerase chain reaction assay was conducted in a Smart Cycler instrument, and the relative levels of DNMT3a, DNMT3b, and DNMT1 mRNAs were normalized relative to that of peptidylprolyl isomerase A. The data are representative of 3 consecutive experiments.\
^\*^*P* \< 0.05 vs. 0 mM aspirin.](aair-11-779-g001){#F1}

There have been few studies on global DNA CpG methylation in NERD. In a genome-wide CpG methylation study of nasal polyps in subjects with NERD and aspirin-tolerant asthma (ATA) patients,[@B35] 332 CpG sites on 296 genes were hypomethylated and 158 sites on 141 genes were hypermethylated in NERD ([Fig. 2](#F2){ref-type="fig"}). Thus, the NERD-associated proportion of global differential methylated CpG (DMC) was 1.78% (490/27,587 CpGs analyzed in the test kit), which was about 10 times higher than the proportion of DMC in the bronchial epithelium of patients with atopic asthma (0.19%, 53/27,578 CpGs).[@B36] The 490 DMCs were located on 437 genes and, thus, the global proportion of differentially methylated genes (DMGs) was 3.02% (437/14,457 genes analyzed in the test kit). In silico analysis of the 490 DMCs indicated that 409 CpG sites (83.5%) were on promoter regions with 130 hypermethylated CpGs and 279 hypomethylated CpGs ([Fig. 3](#F3){ref-type="fig"}). In general, hypermethylation of cytosines within CpG islands of promoters causes gene silencing, and hypomethylation triggers active transcription.[@B37][@B38] Thus, differential promoter CpG methylation may affect gene expression levels in nasal polyps of NERD patients, as compared to ATA patients. Ontological classification of the 36,127 genes in AmiGo2 (<http://amigo.geneontology.org/amigo/search/ontology>) indicated 259 genes in the arachidonate pathways ([Table 2](#T2){ref-type="table"}). Among them, 66 genes were differentially methylated (25.5%), which was 10 times higher than the global proportion of DMG (3.02%). These observations indicated that the genes in the arachidonate pathways are much more labile to CpG methylation in NERD compared to ATA.

![CpG DNA methylation patterns of nasal polyps and peripheral blood mononuclear cells obtained from subjects with NERD and ATA. Volcano plot of differential methylation levels between NERD and ATA in nasal polyp tissues (A) and buffy coat samples (B). Red dots, delta beta ≥ 0.5 and *P* ≤ 0.01; blue dots, delta beta ≤ −0.5 and *P* ≤ 0.01; gray dots, −0.5 ≤ delta beta ≤ 0.5 and *P* \> 0.01. Delta beta, difference in DNA methylation level (subtracting DNA methylation level of ATA from NERD). −log (p), log-transformed *t*-test *P* values. (C) Heat map of 490 differentially methylated CpGs between NERD and ATA in buffy coat and nasal polyps. Reproduced with permission from *Allergy Asthma Immunol Res* 2013;5:258-76[@B19] (license number: EU826007151).\
NERD, nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease; ATA, aspirin-tolerant asthma.](aair-11-779-g002){#F2}

![In silico analysis of the 490 DMCs between NERD and ATA indicated that 409 CpG sites (83.5%) were on promoter regions with 130 hypermethylated CpGs and 279 hypomethylated CpGs.\
DMC, differential methylated CpG; NERD, nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease; ATA, aspirin-tolerant asthma; TSS200, 0--200 bases upstream of the transcription start site; TSS1500, 200--1,500 bases upstream of the transcription start site.](aair-11-779-g003){#F3}

###### Proportions of differently methylated and SNP genes in arachidonic acid pathways in NERD compared to those in ATA
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  Ontology                             No. of genes   DMG         SNP-gene    DMG & SNP   cgSNPs
  ------------------------------------ -------------- ----------- ----------- ----------- ------------
  Arachidonic acid binding             5              3 (60)      2 (40)      1 (20)      1 (20)^\*^
  Arachidonic acid metabolism          62             34 (54.9)   11 (17.8)   4 (6.5)     0 (0)
  Prostaglandin biosynthetic process   25             6 (25)      5 (20)      0 (0)       0 (1)
  Leukotriene biosynthetic process     20             3 (15)      4 (20)      1 (5)       0 (2)
  Arachidonic acid products            93             13 (14)     13 (14)     0 (0)       0 (3)
  Leukotriene products                 38             5 (13)      9 (24)      1 (2.6)     0 (4)
  Lipoxygenase                         16             2 (12.5)    5 (31.3)    0 (0)       0 (5)
  Total                                259            66 (22.5)   49 (18.9)   7 (2.7 )    1 (0.4)

Values are presented as number (%). The 259 genes were recruited from 36,127 genes in the AmiGo2, the web-based set of tools for searching and browsing the Gene Ontology database. Number in parenthesis is proportion of genes among the total gene.

NERD, nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease; DMG, differentially methylated gene; SNP, single nucleotide polymorphism; ATA, aspirin-tolerance asthma; SNP-gene, number of genes having single nucleotide polymorphism associated with nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease; cgSNPs, CpG site related single nucleotide polymorphisms.

^\*^S100A9 (S100 Calcium Binding Protein A9); This protein is a calcium- and zinc-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response.

GENOME-EPIGENOME INTERACTION VIA CpG SITE-RELATED SNPs (cgSNPs)
===============================================================

Some SNPs influence the presence of CpG sites, where DNA modification, such as methylation and hydroxymethylation, occurs.[@B39] These SNPs can lead to gain or loss of CpG sites and are defined as cgSNPs. For example, a C-to-T transition on the "C" of CpG dinucleotides leads to loss of a CpG site. A human genome study demonstrated a considerable proportion of cgSNPs (23.0%) among 4097556 common variants.[@B40] In the nasal polyps of NERD,[@B35] 42 cgSNPs were present in about 11% of the 409 DMC sites on the promoter and one cgSNP was located in the body of the gene ([Table 3](#T3){ref-type="table"}). Forty-seven TFs were predicted to bind to the DNA sequences of these sites ([Fig. 4](#F4){ref-type="fig"}) on PROMO search (<http://alggen.lsi.upc.edu/> [)]{.ul}. Among the TFs, XBP-1, GR-alpha, and EKNTF-1 bind to more than 10 CpGs sites. The XBP-1 protein is a TF that regulates the expression of genes important to the immune system and the cellular stress response.[@B41] In addition, the expression of this protein is required for transcription of a subset of class II major histocompatibility genes.[@B42] GWAS studies performed by our group and other investigators have revealed that SNPs on HLA-DPB1 (rs1042151 and rs3128965) show the most significant association with NERD susceptibility.[@B43] The rs1042151 acts as a potential cis regulator of the expression of *HLA-DPB1* with an expression quantitative trait loci (eQTL) score of 36.83, as calculated using the eQTL browser (<http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/>). In silico analysis of SNP function indicated that the rs1042151 SNP is located in an exonic splicing enhancer region.[@B44] Thus, XBP-1 is thought to be one of the key TFs binding to the DMCs in the development of NERD, which will be validated in future studies.

###### List of 42 cgSNPs of 409 differentially methylated CpG sites between NERD and ATA and their transcription binding factors
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  Gene name   Description                                                              Chromosome   CpG coordinate   Position   DeltaBeta (AIA-ATA)   *P* value   SNP           Genotype   Transcription factor
  ----------- ------------------------------------------------------------------------ ------------ ---------------- ---------- --------------------- ----------- ------------- ---------- ---------------------------------------------------
  PIK3CG      Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma   7            106293008        TSS200     −0.58                 8E-05       rs189643115   C/T        GCF, TFII-I
  SLA         Src like adaptor                                                         8            134141793        TSS200     −0.56                 5E-04       rs193193464   A/G/T      TFIID, GCF
  DOK2        Docking protein 2                                                        8            21827392         TSS1500    −0.55                 2E-04       rs116745856   A/G        ENKTF-1, AP-2alphaA
  EVL         Enah/vasp-like                                                           14           99601344         TSS200     −0.55                 2E-04       rs142509033   A/G        RXR-alpha, ENKTF-1, E2F-1, Pax-5, p53, sp1, WT1
  ARHGAP15    Rho GTPase activating protein 15                                         2            143602842        TSS1500    −0.54                 4E-05       rs145004467   C/T        XBP-1, ENKTF-1, E2F-1, AhR:Arnt
  GPR77       Complement component 5a receptor 2                                       19           52530972         TSS1500    −0.54                 1E-04       rs190777242   A/G        TFII-I, PEA3, XBP-1
  PLD4        Phospholipase D family member 4                                          14           104462063        TSS200     −0.53                 3E-04       rs138509471   A/G        GR-alpha, AP-2alphaA, ENKTF-1, Pax-5, p53, E2F-1
  LILRA2      Leukocyte immunoglobulin like teceptor A2                                19           59776830         TSS1500    −0.52                 6E-05       rs73612405    C/T        XBP-1
  EGFL7       EGF like domain multiple 7                                               9            138676375        TSS1500    −0.52                 9E-05       rs111978941   A/G/T      AR, TFII-I
  ITGAM       Integrin subunit alpha M                                                 16           31178510         TSS1500    −0.52                 1E-03       rs184907050   A/G        USF2, GCF, AP-2alphaA
  TYROBP      TYRO protein tyrosine kinase binding protein                             19           41091889         TSS1500    −0.51                 3E-04       rs146068432   C/T        XBP-1
  TSPAN32     Tetraspanin 32                                                           11           2279317          Body       −0.51                 9E-05       rs74048220    C/G/T      ENKTF-1, GR-alpha, AP-2alphaA
  NALP12      NLR family pyrin domain containing 12                                    19           59019592         TSS200     −0.5                  7E-05       rs187459687   A/G        E2F-1, c-Ets-1, STAT1beta, NF-AT1, IRF-1
  PUM2        Pumilio RNA binding family member 2                                      2            20391116         TSS1500    0.5                   7E-04       rs114135728   C/T        XBP-1, ENKTF-1, AR
  METTL4      Methyltransferase like 4                                                 18           2562965          5\'UTR     0.5                   2E-03       rs200286634   C/T        GR-beta, C/EBPbeta, TFIID
  KLK11       Kallikrein related peptidase 11                                          19           56223296         TSS1500    0.5                   6E-05       rs183746430   A/G        GR-alpha, TFIID, RXR-alpha
  TSPAN8      Tetraspanin 8                                                            12           69838603         TSS1500    0.5                   2E-04       rs77641542    A/G        GR-beta, AP-1, XBP-1
  MYOZ3       Myozenin 3                                                               5            150020473        TSS200     0.5                   1E-03       rs188156985   A/G        GR-alpha, RXR-alpha
  CHRNA10     Cholinergic receptor nicotinic alpha 10 subunit                          11           3649733          TSS1500    0.5                   3E-03       rs190940880   A/G        FOXP3, IRF-1, TFII-I, STAT4, c-Ets-1
  LGALS8      Galectin 8                                                               1            234746847        TSS1500    0.5                   2E-03       rs192328273   A/G        
  UGT1A6      UDP glucuronosyltransferase family 1 member A6                           2            234264888        TSS200     0.51                  5E-05       rs45594938    A/C/G/T    ENKTF-1, c-Myb, RXR-alpha
  SYCP2       Synaptonemal complex protein 2                                           20           57940627         TSS200     0.52                  1E-06       rs140425806   C/G        GR-alpha, GATA-1, HNF-1C, HNF-1B
  SERPINB13   Serpin family B member 13                                                18           59405541         5\'UTR     0.52                  3E-03       rs73468602    C/T        AhR:Arnt,XBP-1
  SH2D4B      SH2 domain containing 4B                                                 10           82287377         TSS1500    0.53                  1E-04       rs137943319   C/T        FOXP3, HNF-3alpha, GR-beta, XBP-1
  NID1        Nidogen 1                                                                1            234304366        TSS1500    0.53                  5E-04       rs187127213   A/C/G      GR-alpha, EBF, T3R-beta1, RXR-alpha
  VTCN1       V-Set domain containing T cell activation inhibitor 1                    1            117555488        TSS1500    0.53                  4E-04       rs146060859   A/G        GR-alpha, YY1
  PCK1        Phosphoenolpyruvate carboxykinase 1                                      20           55569418         TSS200     0.53                  1E-04       rs146925480   A/G        PR B, PR A, p53, Pax-5, AhR:Arnt
  TECTA       Tectorin alpha                                                           11           120478484        TSS200     0.54                  6E-04       rs79614045    C/T        XBP-1, c-Jun, YY1, Ik-1
  LAMB3       Laminin subunit beta 3                                                   1            207892479        TSS200     0.54                  4E-04       rs191233438   C/T        RXR-alpha, E2F-1, Pax-5, p53, GR-alpha, EBF
  RIPK1       Receptor interacting serine/threonine kinase 1                           6            3021353          TSS1500    0.54                  1E-04       rs186932816   C/T        c-Ets-1, c-Myb, IRF-1, YY1
  SLC39A2     Solute carrier family 39 member 2                                        14           20537113         TSS200     0.54                  8E-07       rs141598581   A/G        GATA-1
  TMEM184A    Transmembrane protein 184A                                               7            1562743          TSS200     0.57                  6E-06       rs73287493    C/T        GR-alpha, AP-2alphaA, ENKTF-1
  LIPC        Lipase C, hepatic type                                                   15           56510949         TSS1500    0.58                  3E-04       rs200997055   A/G        XBP-1, c-Jun, ATF3
  CDH26       Cadherin 26                                                              20           57966838         TSS200     0.59                  2E-04       rs188408166   A/G        E2F-1, c-Ets-1, Elk-1
  TNKS1BP1    Tankyrase 1 binding protein 1                                            11           56846646         5\'UTR     0.59                  2E-05       rs113688171   G/T        GR-beta, NFI/CTF
  PFDN2       Prefoldin subunit 2                                                      1            159355726        TSS1500    0.6                   2E-04       rs200278216   C/T        RAR-beta:RXR-alpha,YY1, XBP-1
  IL22RA1     Interleukin 22 receptor subunit alpha 1                                  1            24342378         TSS200     0.6                   7E-05       rs138275016   A/C/G      c-Ets-2, TFII-I, c-Ets-1, Elk-1
  PAQR6       Progestin and AdipoQ receptor family member 6                            1            154484566        TSS200     0.6                   7E-05       rs144755038   A/C        GR-alpha, C/EBPbeta
  GCNT4       Glucosaminyl (N-acetyl) transferase 4                                    5            74363037         TSS1500    0.61                  5E-05       rs73122571    A/G        GR-alpha, PR B, PR A, AP-2alphaA, SRF, Pax-5, p53
  ACKR2       Atypical chemokine receptor 2                                            3            42825852         TSS200     0.63                  3E-05       rs117154133   C/T        XBP-1, AR, AP-1, c-Jun
  CCN4        Cellular communication network factor 4                                  8            134271552        TSS1500    0.64                  1E-04       rs138160356   C/T        c-Myc, c-Jun, USF1, XBP-1, ATF3
  RDH5        Retinol dehydrogenase 5                                                  12           54400422         1stExon    0.66                  2E-04       rs185215037   C/T        
  SLC28A1     Solute carrier family 28 member 1                                        15           83227915         TSS1500    0.7                   6E-05       rs139316942   C/T        C/EBPbeta, GR

cgSNP, CpG site-related single nucleotide polymorphism; NERD, nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease; AIA, aspirin-induced asthma; ATA, aspirin-tolerant asthma; SNP, single nucleotide polymorphism.

![Diagram of transcription factors binding to 43 CpG site-related single nucleotide polymorphisms.](aair-11-779-g004){#F4}

Interestingly, the frequency of cgSNPs was much lower in the arachidonate pathways. Among the total of 259 genes involved in these pathways, the number of genes with SNPs associated with NERD was 49 (18.9%), which was slightly less than the proportion of DMG (25.5%) ([Table 3](#T3){ref-type="table"}). Seven genes had both DMCs and SNPs. Among them, only one SNP (rs19980990 of S100A9) was related to a CpG site (i.e., a cgSNP). Thus, among the 259 genes, gene expression may be regulated by CpG methylation on 59 genes, by SNPs on 42 genes, and by both CpG methylation and SNPs on 7 genes.

DIFFERENTIALLY METHYLATED CpGs OF THE GENES INVOLVED IN THE PG AND LTR BIOSYNTHESIS PATHWAYS
============================================================================================

Among 37 CpGs on 19 genes found in the PG and LT biosynthesis pathways ([Supplementary Table S1](#S1){ref-type="supplementary-material"}), there were 14 DMCs on 11 genes, i.e., *ALOX12* (*cg03760483*, *cg08946332*), *ALOX12B* (*cg03742272*), *ALOX15* (*CG15843823*), *ALOX15B* (*CG15799267*, *CG12343777*), *ALOX5AP* (*CG08529529*), *LOXHD1* (*cg17903316*), *PGDS* (*cg12554857*), *PTGDS* (*CG00563932*), *PTGES* (*cg26672426*, *cg17683775*), *PTGIS* (*CG07612655*), and *TBXAS1* (*CG14116569*) ([Fig. 5](#F5){ref-type="fig"}). Among them, *PGDS* (*cg12554857*) and *ALOX5AP* (*CG08529529*) were highly hypomethylated (delta beta: −0.67 and −0.522, respectively), while *PTGES* (*cg26672426*) was robustly hypermethylated (delta beta: 0.56) in NERD compared to ATA ([Fig. 5](#F5){ref-type="fig"}). Although the genomic impact of DMCs in NERD has not been analyzed with regard to changes in their genes or metabolites, prostanglandins, cysteinyl LTs, and thromboxanes are expected to be elevated, while PGE may be downregulated by varying the extent of CpG methylation of the relevant genes of NERD patients.

![Delta beta values of 16 DMCs (*P* \< 0.05) on 11 genes involved in the prostaglandin and leukotriene pathways between NERD and ATA. Delta beta was calculated by subtracting the beta value of ATA from that of NERD at each CpG site.\
DMC, differential methylated CpG; NERD, nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease; ATA, aspirin-tolerant asthma.](aair-11-779-g005){#F5}

Therapeutic concentrations of aspirin mainly inhibit cyclooxygenase 1 (COX-1). COX-1, also known as PGG/H synthase 1, PG-endoperoxide synthase 1, or PGH2 synthase 1, is an enzyme encoded in humans by the *PTGS1* gene. Therefore, blocking of COX-1 results in a reduction of multifunctional PGH2 level, which is a common precursor substrate for PGD2, PGE2, PGF2, PGI2, and TXB2 ([Fig. 6A](#F6){ref-type="fig"}). Accordingly, the levels of all of these end products are expected to be decreased after aspirin challenge or even in the basal state in NERD. However, systemic PGF2[@B45] and PGD2 levels[@B46] and the ratio of local PGD2/PGE2 levels were increased in NERD[@B47] compared to ATA ([Fig. 6B-E](#F6){ref-type="fig"}). These data are in good agreement with the methylation changes of these genes.

![Effects of aspirin and NSAID on prostaglandin and leukotriene metabolites. Theoretical hanges in PGDs followed by inhibition of COX-1 and actual results (A).[@B47] Changes in PGD2 (B), LTC4 (C), and TXB2 (D) levels in plasma after aspirin challenge in patients with NERD and in those with ATA (license number: 4483431214000).[@B46][@B48]\
NSAID, nonsteroidal anti-inflammatory drug; PGD, prostaglandin D; NERD, nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease; ATA, aspirin-tolerant asthma.\
^\*^*P* \< 0.05; ^†^*P* \< 0.005.](aair-11-779-g006){#F6}

Although systemic basal TBX2 levels were significantly higher in NERD than ATA, the levels were downregulated after aspirin challenge,[@B48] while PGF2 and PGD2 levels were persistently elevated.[@B45][@B46] The different responses to aspirin challenge may be due to genetic differences in these genes between NERD and ATA. A genetic variant study of a Korean population demonstrated that the frequency of the minor allele +*141931T*\>*A* (rs6962291) in intron 9 of *TBXAS1* was significantly lower in the NERD group than the ATA group ([Table 1](#T1){ref-type="table"}). Taken together, these observations suggest that DNA CpG methylation may exert a regulatory role in synthesis of PG metabolites, especially *PGD2* and *PGE*, while the genetic variants and hypomethylation of *TBX2* may be responsible for that of thromboxane B2.[@B49]

The other important mechanistic evidence for NERD pathogenesis supports intrinsic dysregulation of the activity of the *5-LO/LTC4S* pathway, i.e., *LTC4S*[@B1] and *ALOX5*[@B4] ([Table 1](#T1){ref-type="table"}). LTC4S is among the most widely reported variants associated with NERD, although its association with NERD across studies is inconsistent.[@B50][@B51] A recent meta-analysis of 13 case--control studies of asthma revealed significantly increased risk in asthmatic patients carrying the CC or AC genotype vs. the AA genotype.[@B16] Three ALOX5 promoter variants are associated with NERD[@B4][@B17][@B18] ([Table 1](#T1){ref-type="table"}). Interestingly, ALOX5AP showed hypomethylation with delta beta of −0.52, which may affect gene expression. Thus, cysteinyl LTs may be elevated by both differences in the extent of methylation of ALOX5AP and genetic variants of ALOX5 and LTC4 synthase. Among the 14 receptor genes involved in the PG and LTR pathways, 5 genes showed 6 DMC ([Supplementary Table S2](#S2){ref-type="supplementary-material"}). However, *LTB4R* and *LXA4 Receptor* (*FPRL1*) are significantly hypomethylated with delta beta \> 0.2 ([Fig. 7](#F7){ref-type="fig"}). As shown in [Table 1](#T1){ref-type="table"}, *CysLTR1* and *CysLTR2*, and *PTGER1*, *PTGER2*, *PTGER3*, and *PTGER4*, *PTGDR*, *PTGD2R* (*CRTH2*), *PTGIR* and *TBXA2R* have different frequencies of SNPs on their respective genes in patients with NERD or those with nasal polyps,[@B52] indicating that the receptors for PG and LTR metabolites have genetic effects due to SNPs except for LTB4R and FPRL1, which are modulated by differences in methylation ([Fig. 7](#F7){ref-type="fig"}).

![Delta beta values of 6 DMCs (*P* \< 0.05) on 5 genes of receptors involved in the prostaglandin and leukotriene pathways between NERD and ATA. Delta beta was calculated by subtracting the beta value of ATA from that of NERD at each CpG site.\
DMC, differential methylated CpG; NERD, nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease; ATA, aspirin-tolerant asthma.](aair-11-779-g007){#F7}

CONCLUSION
==========

PGE synthesis may be decreased due to hypermethylation of PGEs, while PGD and thromboxane synthesis may be elevated by hypomethylation of PTDS and TBXAS. The imbalance of PGE/PGD may be accentuated by genetic variants of PGERs (EP2--EP4) and PTGDR. In the LT pathways, cysteinyl LTR synthesis may be elevated by hypomethylated ALOX5AP and genetic variants of ALOX5 and LTC4S. Furthermore, the effects of cysteinyl LT may be maximized by genetic variants of CysLR1 and 2 ([Fig. 8](#F8){ref-type="fig"}). Accordingly, the imbalance of PG/cysteinyl LT synthesis may be dominantly regulated by the changes in methylation and may be complemented by the SNPs of LTC4S and ALOX5, and the effects of the imbalance may be accentuated by the genetic variants of PGERs, CYSLTR1, and CYSLTR2 ([Fig. 8](#F8){ref-type="fig"}). Taken together, these observations indicated that subjects with NERD may have genetically distorted and epigenetically susceptible arachidonate pathways to environmental factors, including exposure to NSAIDs or other agents. In addition, DNA methylation may indeed be tightly regulated by genetic factors such as SNPs that affect NERD development ([Fig. 8](#F8){ref-type="fig"}). However, the precise mechanisms by which NSAIDs induce dysregulation of CpG methylation in NERD are still unknown. It remains to be determined when and how the epigenetic effects of NSAIDs begin and the initial mechanisms underlying the changes in CpG methylation. Other possible actions of NSAID may involve modification of other epigenetic components, including histone proteins and miRNA, or altered metabolism of methylating nutrients. Although the molecular mechanisms underlying NERD pathogenesis remain poorly understood, genetic and epigenetic variations play significant roles. Our results enhance the understanding of the genetic and epigenetic mechanisms involved in NERD development and suggest new approaches toward the diagnosis, treatment, and management of NERD.

![NERD severity and its clinical phenotypes are affected by DNA methylation and genetic variation within genes of associated with multiple pathways for arachidonic acid metabolism.\
NERD, nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease; PG, prostaglandin; SNP, single nucleotide polymorphism; ASA, acetylsalicylic acid ; DP, prostaglandin D (PGD) receptors; EP, prostaglandin E (PGE) receptors; FP, prostaglandin F receptor; IP, prostaglandin I2 receptor; TP, thromboxane receptors; LT, leukotriene; BLT, leukotriene B4 receptor; ALOX5, arachidonate 5-lipoxygenase; 5-HPETE, arachidonic acid 5-hydroperoxide; CysLTR1, cysteinyl leukotriene receptor 1; CysLTR2, cysteinyl leukotriene receptor 2; LTC4S, leukotriene C4 synthase; LTA4H, aeukotriene A4 hydrolase.](aair-11-779-g008){#F8}

This study was supported by a grant from the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2017R1D1A1B0429365) and a research grant from Soonchunhyang University to JS Park. The methylation data were generously provided by a Biobank in Soonchunhyang University, Bucheon Hospital. JU Lee was supported by the Basic Science Research Program of NRF (2018R1A6A3A01011004). The data were obtained from a BioBank at Soonchunhyang University, Bucheon Hospital.

**Disclosure:** There are no financial or other issues that might lead to conflict of interest.

SUPPLEMENTARY MATERIALS
=======================

###### Supplementary Table S1

Delta beta levels of differentially methylated CpGs in prostaglandin and leukotriene pathways between NERD and ATA

###### Supplementary Table S2

DNA methylation level of differentially methylated CpGs in receptor genes of arachidonic acid pathways in AIA compared to those in ATA

[^1]: ^†^Jong-Uk Lee and Jong Sook Park contributed equally to this work.
